Anti-CD96 antibodies and methods of use thereof
The present disclosure provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human CD96 receptor protein (hu-CD96) and are capable of decreasing, inhibiting, and/or fully-blocking immune regulatory effects mediated by hu-CD96. The present disclosure also provides methods of using the antibodies (and compositions thereof) to treat diseases and conditions responsive to decreasing, inhibiting and/or blocking immune regulatory function or activity mediated by CD96 binding to CD155, including effects arising from CD96 interactions with CD226 and/or TIGIT.
1. A method of treating a CD96 mediated disease in a subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an anti-CD96 antibody and a pharmaceutically acceptable carrier, wherein the anti-CD96 antibody comprises: (i) a first light chain hypervariable region (HVR-L1), a second light chain hypervariable region (HVR-L2), and a third light chain hypervariable region (HVR-L3), and (ii) a first heavy chain hypervariable region (HVR-H1), a second heavy chain hypervariable region (HVR-H2), and a third heavy chain hypervariable region (HVR-H3); wherein:
a) HVR-L1 comprises SEQ ID NO: 13, HVR-L2 comprises SEQ ID NO: 14, HVR-L3 comprises SEQ ID NO: 15, HVR-H1 comprises SEQ ID NO: 41, HVR-H2 comprises SEQ ID NO: 42, and HVR-H3 comprises SEQ ID NO: 43;
b) HVR-L1 comprises SEQ ID NO: 13, HVR-L2 comprises SEQ ID NO: 14, HVR-L3 comprises SEQ ID NO: 15, HVR-H1 comprises SEQ ID NO: 95, HVR-H2 comprises SEQ ID NO: 42, and HVR-H3 comprises SEQ ID NO: 43;
c) HVR-L1 comprises SEQ ID NO: 13, HVR-L2 comprises SEQ ID NO: 14, HVR-L3 comprises SEQ ID NO: 15, HVR-H1 comprises SEQ ID NO: 41, HVR-H2 comprises SEQ ID NO: 112, and HVR-H3 comprises SEQ ID NO: 43;
d) HVR-L1 comprises SEQ ID NO: 13, HVR-L2 comprises SEQ ID NO: 14, HVR-L3 comprises SEQ ID NO: 15, HVR-H1 comprises SEQ ID NO: 41, HVR-H2 comprises SEQ ID NO: 42, and HVR-H3 comprises SEQ ID NO: 221;
e) HVR-L1 comprises SEQ ID NO: 37, HVR-L2 comprises SEQ ID NO: 38, HVR-L3 comprises SEQ ID NO: 39, HVR-H1 comprises SEQ ID NO: 65, HVR-H2 comprises SEQ ID NO: 66, and HVR-H3 comprises SEQ ID NO: 67; or
f) HVR-L1 comprises SEQ ID NO: 13, HVR-L2 comprises SEQ ID NO: 14, HVR-L3 comprises SEQ ID NO: 15, HVR-H1 comprises SEQ ID NO: 95, HVR-H2 comprises SEQ ID NO: 112, and HVR-H3 comprises SEQ ID NO: 221.
2. The method of claim 1 , wherein the anti-CD96 antibody comprises a light chain variable domain (VL) amino acid sequence having at least 90% identity to SEQ ID NO: 68, and a heavy chain variable domain (VH) amino acid sequence having at least 90% identity to SEQ ID NO: 272.
3. The method of claim 2 , wherein the anti-CD96 antibody comprises: the light chain variable domain (VL) amino acid sequence of SEQ ID NO: 68, and the heavy chain variable domain (VH) amino acid sequence of SEQ ID NO: 272.
4. The method of claim 1 , wherein the anti-CD96 antibody comprises a light chain (LC) amino acid sequence having at least 90% identity to SEQ ID NO: 454, and a heavy chain (HC) amino acid sequence having at least 90% identity to SEQ ID NO: 492.
5. The method of claim 4 , wherein the anti-CD96 antibody comprises: the light chain (LC) amino acid sequence of SEQ ID NO: 454, and the heavy chain (HC) amino acid sequence of SEQ ID NO: 492.
6. The method of claim 1 , wherein the anti-CD96 antibody is characterized by at least one of the following properties:
a) binds to human CD96 with a binding affinity of 1×10 −8 M or less;
b) binds to cynomolgus monkey CD96 with a binding affinity of 1×10 −8 M or less;
c) binds to human CD96 isoform 1 expressed on a cell with an antibody EC 50 concentration of 5 nM or less;
d) binds to human CD96 isoform 2 expressed on a cell with an antibody EC 50 concentration of 5 nM or less;
e) binds to cynomolgus monkey PBMCs with an antibody EC 50 concentration of 5 nM or less, 1 nM or less, or 0.1 nM or less;
f) decreases binding of human CD155 to human CD96 expressed on CHO cells by at least 90%;
g) increases IFNγ secretion from human PBMCs by at least 1.8-fold;
h) increases IL-2 secretion from human PBMCs by at least 1.8-fold;
i) binds to human and/or cynomolgus monkey CD226 expressed on cells;
j) binds to human CD226 with a binding affinity of 1 μM or less, 900 nM or less, 800 nM or less, 700 nM or less, from 1 μM to 50 nM, or from 800 nM to 200 nM; optionally, wherein the binding affinity is measured by equilibrium dissociation constant (K D ) to a hu-CD226 polypeptide of SEQ ID NO: 482; and
k) binds to cynomolgus monkey CD226 with a binding affinity of 1 μM or less, 800 nM or less.
7. The method of claim 1 , wherein the anti-CD96 antibody binds to human CD96 with a binding affinity of 1×10 −8 M or less, 1×10 −9 M or less, 1×10 −10 M or less, or 1×10 −11 M or less and wherein the binding affinity is measured by equilibrium dissociation constant (K D ) to a hu-CD96 polypeptide of SEQ ID NO: 4.
8. The method of claim 1 , wherein the anti-CD96 antibody binds to cynomolgus monkey CD96 with a binding affinity of 1×10 −8 M or less, 1×10 −9 M or less, 1×10 −10 M or less, or 1×10 −11 M or less and wherein the binding affinity is measured by equilibrium dissociation constant (K D ) to a cy-CD96 polypeptide of SEQ ID NO: 7.
9. The method of claim 1 , wherein the anti-CD96 antibody binds to human CD96 isoform 1 expressed on a cell with an anti-CD96 antibody EC 50 concentration of 5 nM or less, 1 nM or less, or 0.1 nM or less and wherein the cell is a HEK293T cell.
10. The method of claim 1 , wherein the anti-CD96 antibody binds to human CD96 isoform 2 expressed on a cell with an antibody EC 50 concentration of 5 nM or less, 1 nM or less, or 0.1 nM or less and wherein the cell is a CHO cell.
11. The method of claim 1 , wherein the anti-CD96 antibody decreases binding of human CD155 to human CD96 expressed on CHO cells by at least 90%, at least 95%, at least 99%, or 100% and wherein at a human CD155 concentration of 10 nM the anti-CD96 antibody has an IC 50 of 5 nM or less, 1 nM or less, or 0.1 nM or less.
12. The method of claim 1 , wherein the anti-CD96 antibody increases IFNγ secretion from human PBMCs by at least 1.8-fold, at least 1.9-fold, at least 2-fold, at least 2.1-fold, or at least 2.20-fold and wherein the anti-CD96 antibody has an EC50 concentration of 0.3 nM or less, 0.2 nM or less, or 0.1 nM or less.
13. The method of claim 1 , wherein the anti-CD96 antibody increases IL-2 secretion from human PBMCs by at least 1.8-fold, at least 1.9-fold, at least 2-fold, at least 2.1-fold, or at least 2.20-fold and wherein the anti-CD96 antibody has an EC 50 concentration of 0.3 nM or less, 0.2 nM or less, or 0.1 nM or less.
14. The method of claim 1 , wherein the anti-CD96 antibody binds to human or cynomolgus monkey CD226 expressed on HEK293 cells, with an anti-CD96 antibody EC 50 concentration of 500 nM or less, 300 nM or less, 250 nM or less, 200 nM or less, 150 nM or less, 100 nM or less, or 50 nM or less.
15. The method of claim 1 , wherein the anti-CD96 antibody binds to human CD226 with a binding affinity of 1 μM or less, 900 nM or less, 800 nM or less, 700 nM or less, from 1 μM to 50 nM, or from 800 nM to 200 nM; and wherein the binding affinity is measured by equilibrium dissociation constant (K D ) to a hu-CD226 polypeptide of SEQ ID NO: 482.
16. The method of claim 1 , wherein the anti-CD96 antibody binds to cynomolgus monkey CD226 with a binding affinity of 1 μM or less, 800 nM or less, 500 nM or less, 300 nM or less, 100 nM or less, from 1 μM to 50 nM, from 500 nM to 60 nM, or from 300 nM to 70 nM; and wherein the binding affinity is measured by equilibrium dissociation constant (K D ) to a cyCD226 polypeptide of SEQ ID NO: 483.
17. The method of claim 1 , wherein the anti-CD96 antibody specifically binds to one or more amino acid residues within domain 1 of hu-CD96, wherein domain 1 comprises the amino acid sequence of SEQ ID NO: 5.
18. The method of claim 1 , wherein the CD96 mediated disease is a viral infection or cancer.
19. The method of claim 18 , wherein the viral infection is selected from is selected from the group consisting of Cytomegalovirus (CMV), Epstein Barr Virus (EBV), Herpes Simplex Virus (HSV), Human Immunodeficiency Virus (HIV), Human Papilloma Virus (HPV), and Varicella Zoster Virus (VSV).
20. The method of claim 18 , wherein the cancer is selected from the group consisting of adrenal gland cancer, bladder cancer, brain cancer, breast cancer, cervical cancer, colorectal cancer, EGJ adenocarcinoma, esophageal cancer, gall bladder cancer, gastric cancer, head and neck cancer, heart cancer, hepatocellular carcinoma, kidney cancer, liver cancer, melanoma, mesothelioma, non-small cell lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, spleen cancer, small cell lung cancer, testicular cancer, thyroid cancer, and uterine cancer; in some embodiments, the cancer is selected from lung cancer, skin cancer (e.g., melanoma), pancreatic cancer, endometrial cancer, prostate cancer, colorectal cancer, ovarian cancer, and bladder cancer.
21. The method of claim 1 , wherein the composition comprises a therapeutically effective amount of the anti-CD96 antibody.
22. The method of claim 1 , wherein the pharmaceutical composition further comprises a chemotherapeutic agent or a second antibody comprising a specificity for an immune checkpoint molecule.
23. The method of claim 22 , wherein the immune checkpoint molecule is selected from the group consisting of: PD1, TIGIT, LAG3, PVRIG, KIR, TIM-3, CRTAM, CTLA-4, BTLA, CD244, CD160, LIGHT, GITR, 4-1BB, OX40, CD27, TMIGD2, ICOS, CD40, CD47, SIRPa, NKG2D, NKG2A, TNFRSF25, CD33, CEA, Epcam, GPC3, CD200, CD200R1, CD73, CD83, CD39, TRAIL, CD226, and VISTA.
24. The method of claim 1 , wherein the anti-CD96 antibody is the sole active agent of the composition.